The aim of the study is to describe patient characteristics (demographic and clinical) and the patterns of use of Quetiapine XR in patients receiving the drug for the first time in real-life practice regardless the final diagnosis.
Description of the use of Quetiapine Extended Release (XR) in real-life practice in France
Study Type
OBSERVATIONAL
Enrollment
2,292
Research Site
Argenteuil, France
Research Site
Belley, France
Research Site
Castelmaurou, France
Descriptive analysis of variables related with how the drug is prescribed and used by the patient.
Variables related with how the drug is prescribed and used by the patient \[doses in mg/day, titration (yes/no), time of administration (morning/middle of the day/afternoon/evening), concomitant treatments\] are going to be described.
Time frame: At inclusion
Description of patient's socio-demographics profile.
Age, gender, educational and professional status, co-habitation are going to be described.
Time frame: At inclusion
Descriptive analysis of medical history.
Diagnosis, family history of psychiatric disorders, number of suicidal attempts within the last 12 months, co-morbidities, treatments received during the last 12 months, laboratory and exam data will be included in the description.
Time frame: At inclusion
Severity of the disease measured by Clinical Global Impressions Scale - Severity (CGI-S).
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients.
Time frame: At inclusion
Change in Clinical Global Impressions Scale - Severity (CGI-S) during the treatment.
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients.
Time frame: From baseline to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Reserach Site
Cavaillon, France
Research Site
Les Mureaux, France
Research Site
Lille, France
Research Site
Marseille, France
Research Site
Montpellier, France
Research Site
Nîmes, France
Research SIte
Obernai, France
...and 9 more locations
Quetiapine XR and concomitant treatment stop, stop date, reasons to stop, restart, restart date, reasons to restart.
Time frame: From baseline to 12 months
Descriptive analysis of the treatment changes: drug switches.
Time frame: From baseline to 12 months
Description of patterns of healthcare management resource use related with psychiatric disorders under investigation.
Time frame: From baseline to 12 months
Change in Body Mass Index (BMI).
Time frame: From baseline to 12 months
Laboratory tests- cholesterol.
Blood test- cholesterol.
Time frame: From baseline to 12 months
Descriptive analysis of all adverse events.
Time frame: From baseline to 12 months
Relapses (only for the schizophrenia subpopulation).
New psychiatric hospitalisation, deterioration of the CGI-S (Clinical Global Impressions Scale - Severity) by at least 3 points for a baseline score of 1, at least 2 points for a baseline score of 2 or 3, at least 1 point for a baseline score of 4.
Time frame: From baseline to 12 months
Laboratory tests- glycemia.
Blood test- glycemia.
Time frame: From baseline to 12 months